Q-omics provides the consensus-scored FAM155A profile across patient tissues and cancer cell-line models. FAM155A expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, FAM155A is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, FAM155A RNA expression shows 15,371 significant gene co-expression associations, with the highest sampling consensus in PCPG. Together, these results highlight KIRP, HNSC, and PCPG as cancer lineages where FAM155A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM155A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM155A survival associations across molecular data types. FAM155A RNA expression shows survival associations in the most cancer types (21), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM155A RNA expression–survival associations across cancer types. High FAM155A expression shows unfavorable associations in KIRP and LUSC, but favorable associations in BRCA, LGG, UCEC and HNSC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRP as the clearest survival context for FAM155A RNA expression.
This table summarizes FAM155A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for FAM155A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM155A shows lower tumor expression in LUSC and higher tumor expression in HNSC, BRCA, THCA, LIHC and CHOL. The HNSC box plot shows higher FAM155A RNA expression in tumor versus normal tissue (log2 FC = +0.139, t-test p = .001).
This table shows molecular features associated with FAM155A in patient tissues and cancer cell lines. In patient samples, FAM155A shows the broadest associations at the RNA and protein expression levels, with PCPG recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM155A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in LIVER and LUNG_SCLC.
